Thanks to the recent acquisition of an ERC grant, I have embarked on an exciting new research expedition that, under different circumstances, would have remained beyond reach. My mission unfolds at the intersection of post-perturbational single-cell transcriptomic data, CRISPR technology, cancer-dependency bioinformatics resources, and cutting-edge machine intelligence. These tools collectively form the backbone of my research endeavors, dedicated to advancing the frontier of early anti-cancer drug discovery.